Clinical impact of the polypill for cardiovascular prevention in Latin America: a consensus statement of the Inter-American Society of Cardiology

Liprandi, Álvaro Sosa; Liprandi, Maria Inés Sosa; Alexánderson, Erick; Avezum, Álvaro; Lanas, Fernando; Lópes-Jaramillo, José Patricio; Ponte-Negretti, Carlos I; Wyss, Fernando; Juanatey, José Ramón González; Perel, Pablo; Negretti, Carlos I Ponte N; Martínez, Felipe.
Glob Heart ; 14(1): 03-16, Mar. 2019. gráfico, tabela
Artículo en Inglés | SES-SP, SESSP-IDPCPROD, SES-SP | ID: biblio-1024845

Documentos relacionados

  1. Marine-Derived Compounds Applied in Cardiovascular Diseases: Submerged Medicinal Industry.
  2. Repurposing of Drugs for Cardiometabolic Disorders: An Out and Out Cumulation.
  3. A Call to Action for New Global Approaches to Cardiovascular Disease Drug Solutions.
  4. Scalability of effective adherence interventions for patients using cardiovascular disease medication: A realist synthesis-inspired systematic review.
  5. Princeton IV consensus guidelines: PDE5 inhibitors and cardiac health.
  6. Marketing research of combined drugs for treatment of cardiovascular diseases.
  7. Immunity and inflammation in cardiovascular disorders.
  8. Low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol and apolipoprotein B for cardiovascular care.
  9. Medical Products for Cardiovascular Disease Management in Nepal: a needs assessment study.
  10. Fibrinolysis in Acute and Chronic Cardiovascular Disease.